Medically Reviewed by Dr. Tashiya Mirando, Written by Nabiha Khalid, Medical Writer
Menopause often brings about significant changes in a woman’s body and mind, including alterations in cognitive function. These changes can be unsettling, but they are generally temporary and not indicative of serious conditions like dementia. Here we explore the role of estrogen—specifically the hormone estradiol—in the brain, discuss how menopause hormone therapy may influence cognition, and review current recommendations from leading menopause organisations.
Clarity and Cognition During Menopause
During the transition to menopause, up to two-thirds of women may notice symptoms often described as “brain fog.” This term can encompass difficulties with memory, focus, or a general feeling of mental cloudiness. Importantly, these symptoms are typically short-term and, based on current research, are not linked to an increased risk of dementia or other neurodegenerative diseases.
The Role of Estrogen in the Brain
Understanding estrogen’s role in brain function has become crucial to unraveling the connection between menopause and cognitive health. As research advances, scientists have uncovered the complex ways this hormone—particularly its form estradiol—influences various aspects of brain function and structure.
Estradiol’s Influence
One key form of estrogen—known as estradiol—declines rapidly during menopause. Estradiol has far-reaching effects on the brain, interacting with dopamine (a neurotransmitter involved in motivation and reward) and supporting energy production in brain cells. It also influences brain volume, the formation of new connections between nerve cells, sleep quality, and mood regulation.
Observational Findings
Research suggests that estrogen could have a protective effect on the brain, potentially helping maintain cognitive function during perimenopause (the period leading up to menopause). Studies have also shown that estrogen fluctuations during this time can significantly impact sleep patterns and mood stability. Observational studies indicate that surgical removal of the ovaries—a primary source of estrogen—may increase the likelihood of memory challenges and the later development of Alzheimer’s disease.
Estrogen plays many important roles in keeping your brain healthy—from giving brain cells energy to helping them communicate with each other. Understanding how estrogen works during menopause could help doctors develop better treatments to protect your memory and mood as you age.
Menopause Hormone Therapy and Cognitive Function
The complex relationship between menopause hormone therapy (MHT) and cognitive function has emerged as a key area of research, with timing playing a crucial role in potential benefits and risks. Studies spanning decades, including the landmark WHI Memory Study, have provided valuable insights into this intricate connection.
Mixed Research Outcomes
Research on menopause hormone therapy (especially treatments with estrogen) has shown different results. Some studies found that starting menopause hormone therapy when menopause begins might help keep the brain healthy and protect memory as women get older. However, other studies found no clear benefits for brain function. In fact, for older women, some studies suggest it might have risks.
Timing Matters
A growing theory, sometimes referred to as the “critical window hypothesis,” suggests that beginning menopause hormone therapy during perimenopause or early menopause may offer more cognitive benefits and fewer risks than initiating treatment later in life. According to observational data, starting menopause hormone therapy in middle age could potentially help ward off dementia.
Insights from the WHI Memory Study
The Women’s Health Initiative (WHI) Memory Study provided additional insights:
- Women over 65 who started a combination of estrogen and progesterone therapy saw an increased risk of dementia. However, those using estrogen alone did not show a statistically significant increase in dementia risk.
- Women who began menopause hormone therapy between the ages of 50 and 55 did not exhibit changes in cognitive test results after an average follow-up of 7 years.
Early Menopause Risks and Treatment
Women who go through premature or early menopause (before age 45) have a higher chance (up to 70%) of developing Alzheimer’s disease later in life. But starting HT before age 50 might help reduce this risk.
Research shows that when you start menopause hormone therapy matters a lot for your cognitive (brain) health. Starting it during the early stages of menopause, or when menopause begins earlier than usual, might help protect your brain. But every woman’s situation is different – the right choice depends on your age, when your menopause started, and your overall health.
Recommendations from Notable Menopause Societies
Despite these findings, major menopause organizations, such as The Menopause Society (previously known as The North American Menopause Society) and British Menopause Society, agree that the evidence is not yet strong enough to recommend menopause hormone therapy solely for cognitive benefits. Key points include:
- Women who initiate menopause hormone therapy before age 60 are unlikely to see an increased risk of dementia or other cognitive impairments.
- At present, MHT cannot be universally recommended to prevent or treat memory decline or dementia at any age.
Medical experts say that menopause hormone therapy appears to be safe for brain health when started before age 60. However, they recommend that women shouldn’t take hormone therapy just to protect their memory or thinking abilities—there should be other reasons too, like managing menopause symptoms.
Conclusion
Menopause can bring noticeable—but often temporary—cognitive changes. Estradiol likely plays a significant role in supporting brain function, and starting menopause hormone therapy early in the menopause transition may have advantages for cognitive health. However, research findings remain mixed, and professional bodies emphasize that more rigorous clinical trials are needed before menopause hormone therapy can be prescribed for its potential cognitive benefits.
Staying informed and consulting with a qualified healthcare professional are crucial steps in making decisions about menopause hormone therapy, especially regarding its timing and potential risks or benefits for brain health.
References
1. British Menopause Society & BMS medical advisory council. (2020). BMS & WHC’s 2020 recommendations on hormone replacement therapy in menopausal women. In BMS | Consensus Statement (pp. 1–52). https://thebms.org.uk/wp-content/uploads/2023/10/02-BMS-ConsensusStatement-BMS-WHC-2020-Recommendations-on-HRT-in-menopausal-women-SEPT2023-A.pdf.
2. McWhirter, L., Ritchie, C., Stone, J., & Carson, A. (2020). Functional cognitive disorders: a systematic review. The lancet. Psychiatry, 7(2), 191–207. https://doi.org/10.1016/S2215-0366(19)30405-5
3. Grainger, S. (n.d.-a). Oestrogen and cognition in the perimenopause and menopause – Australasian Menopause Society. https://www.menopause.org.au/hp/information-sheets/oestrogen-and-cognition-in-the-perimenopause-and-menopause
4. Russell, J. K., Jones, C. K., & Newhouse, P. A. (2019). The role of estrogen in brain and cognitive aging. Neurotherapeutics, 16(3), 649–665. https://doi.org/10.1007/s13311-019-00766-9
5. Henderson, V. W. (2013). Alzheimer’s disease: Review of hormone therapy trials and implications for treatment and prevention after menopause. The Journal of Steroid Biochemistry and Molecular Biology, 142, 99–106. https://doi.org/10.1016/j.jsbmb.2013.05.010
6. Whitmer, R. A., Quesenberry, C. P., Zhou, J., & Yaffe, K. (2010). Timing of hormone therapy and dementia: The critical window theory revisited. Annals of Neurology, 69(1), 163–169. https://doi.org/10.1002/ana.22239
7. Georgakis, M. K., Beskou-Kontou, T., Theodoridis, I., Skalkidou, A., & Petridou, E. T. (2019). Surgical menopause in association with cognitive function and risk of dementia: A systematic review and meta-analysis. Psychoneuroendocrinology, 106, 9–19. https://doi.org/10.1016/j.psyneuen.2019.03.013
8. Faubion et al. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause the Journal of the North American Menopause Society, 29(7), 767–794. https://doi.org/10.1097/gme.0000000000002028